[go: up one dir, main page]

WO2020230090A1 - Compositions orales de sulfate ferreux - Google Patents

Compositions orales de sulfate ferreux Download PDF

Info

Publication number
WO2020230090A1
WO2020230090A1 PCT/IB2020/054592 IB2020054592W WO2020230090A1 WO 2020230090 A1 WO2020230090 A1 WO 2020230090A1 IB 2020054592 W IB2020054592 W IB 2020054592W WO 2020230090 A1 WO2020230090 A1 WO 2020230090A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
iron salt
salt compositions
mesh
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/054592
Other languages
English (en)
Inventor
Shrinivasan SHESHA IYENGAR
Chandanmal pukhraj BOTHRA
Hemanth Kumar BOTHRA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nokha Trading LLP
Original Assignee
Nokha Trading LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nokha Trading LLP filed Critical Nokha Trading LLP
Priority to AU2020275505A priority Critical patent/AU2020275505A1/en
Publication of WO2020230090A1 publication Critical patent/WO2020230090A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to iron salt oral compositions.
  • the present invention specifically relates to iron salt granules and buccal tablets compositions.
  • the present invention specifically relates to compositions of granules and buccal tablets comprising ferrous sulphate as active ingredient, penetration/absorption enhancers and pharmaceutically acceptable excipients.
  • the present invention relates to composition of granules and buccal tablets comprising ferrous sulphate hydrate as active ingredient, anti-oxidant, mouth melting agent, taste masking agents as penetration/absorption enhancers, reducing agent, binding agent, sweetening agent, disintegrant, flavouring agent and lubricants as pharmaceutically acceptable excipients for preventing anemia.
  • the present invention more specifically relates to process for the preparation of ferrous sulphate granules using wet granulation technique comprising the steps of sifting, granulating, drying and filling into sachets.
  • the present invention more specifically relates to process for the preparation of ferrous sulphate buccal tablets using wet granulation technique comprising the steps of sifting, granulating, drying and compressing.
  • Iron deficiency anemia arises when the balance of iron intake, iron storage are insufficient to fully support production of erythrocytes. Iron deficiency anemia rarely causes death, but the impact on human health is significant. Iron in a variety of forms is administered for the treatment of iron deficiency and related disorders (e.g., anemia) as well as prophylactically to supply the minimum daily recommended allowance. A variety of iron compounds have been administered, including ferric and ferrous forms of elemental iron as salts, complexes, hydrates, chelates, and bound to polymer.
  • Iron is administered either parenterally or orally. Iron is administered orally via various iron preparations, including solutions, tablets or enteric coated preparations. The most common forms of oral iron preparations are ferrous sulfate and ferrous gluconate. Ferrous sulfate is less expensive and has more elemental iron in it.
  • Ferrous sulphate is available in the market as tablets, capsules, drops, liquid and syrups.
  • Oral iron preparations have many disadvantages. First and foremost, they cause gastrointestinal side effects including nausea, bloating, constipation, and diarrhoea. This leads to discontinuation of iron supplementation in approximately 40-66% of the patients taking such supplements. Furthermore, the absorption of iron is variable and affected by the oral ingestion of other compounds. For example, oral ingestion of food products reduces iron absorption by approximately 50%, which is problematic since many patients take iron with food in order to reduce the gastrointestinal side effects.
  • iron deficiency anemia respond poorly to oral iron supplementation, because iron cannot be properly absorbed through the cells of the gastrointestinal system. This is especially true of certain inflammatory conditions of the bowel, such as Crohn's disease. Additionally, diseases associated with functional iron deficiency, such as the anemia of renal failure are also associated with limited absorption of orally administered iron.
  • WO 2015/004519 discloses divalent iron compound for use in hyposideremia therapy by administration through intrabuccal absorption in a patient, wherein said administration occurs with indication to the patient to avoid swallowing the formulation containing the divalent iron compound and/or saliva for a period of time of at least 30 seconds after placement of the formulation containing the divalent iron compound in the intrabuccal cavity, said use providing for the administration of divalent iron at doses comprised in an interval from 1 to 90 mg of divalent Fe per day for a human patient to reduce, for an equal increment in transferrin saturation, the onset of free non transferrin bound iron with respect to gastrointestinal administration. It also discloses ferrous sulfate as divalent iron compound.
  • the inventors of the present invention have developed compositions of ferrous sulphate granules and buccal tablets with increased bio absorption for preventing anemia which is devoid of the disadvantages of prior-art.
  • the inventors of the present invention provide process for the preparation of ferrous sulphate granules using wet granulation technique comprising the steps of sifting, granulating, drying and filling into sachets.
  • the inventors of the present invention also provide process for the preparation of ferrous sulphate buccal tablets using wet granulation technique comprising the steps of sifting, granulating, drying and compressing.
  • the main objective of the present invention is to provide iron salt oral compositions.
  • Another objective of the present invention is to provide iron salt granules and buccal tablets.
  • Another objective of the present invention is to provide composition of ferrous sulphate granules, buccal tablets and methods for preparation thereof.
  • Another objective of the present invention is to provide granules and buccal tablets compositions comprising ferrous sulphate hydrate as active ingredient, penetration/absorption enhancers and pharmaceutically acceptable excipients.
  • Another objective of the present invention is to provide granules and buccal tablet compositions comprising ferrous sulphate hydrate as active ingredient, anti oxidant, mouth melting agent, taste masking agents as penetration/absorption enhancers, reducing agent, binding agent, sweetening agent, disintegrant, flavouring agent and lubricants as pharmaceutically acceptable excipients for preventing anemia.
  • the present invention provides compositions of iron salt oral compositions.
  • Another embodiment of the present invention relates to iron salt granules and buccal tablets for preventing anemia.
  • Another embodiment of the present invention relates to iron salt granules and buccal tablets comprising ferrous sulphate as active ingredient, penetration/absorption enhancers and pharmaceutically acceptable excipients.
  • Another embodiment of the present invention relates to granules and buccal tablets comprising ferrous sulphate hydrate as active ingredient, anti-oxidant, mouth melting agent, taste masking agents as penetration/absorption enhancers, reducing agent, binding agent, sweetening agent, disintegrant, flavouring agent and lubricants as pharmaceutically acceptable excipients for preventing anemia.
  • Another embodiment of the present invention relates to granules and buccal tablets comprising ferrous sulphate hydrate as active ingredient and ascorbic acid as anti-oxidant, mannitol as mouth melting agent, sodium chloride, citric acid and whey protein as taste masking agents, fructose as reducing agents, PVP-K30 as binding agent, sucralose or stevia as sweetening agents, crospovidone as disintegrant, lemon flavour as flavouring agent, aerosil and purified talc as lubricants.
  • Another embodiment of the present invention relates to provide process for the preparation of ferrous sulphate granules using wet granulation technique comprising the steps of sifting, granulating, drying and filling into sachets.
  • Another embodiment of the present invention relates to provide process for the preparation of ferrous sulphate buccal tablets comprising the steps of sifting, granulating, drying and compressing.
  • compositions of granules and buccal tablets comprising:
  • flavouring agent 1% to 10% (w/w) of flavouring agent
  • the present invention provides process for preparing granules and buccal tablets, wherein the process comprising steps of:
  • step (d) adding above sifting ingredients to obtained dried granules of step (b),
  • step (e) sifting flavouring agent through #100 mesh, lubricant through #60 mesh and adding to obtained blend of step (d) followed by mixing for 10 minutes, (f) sifting lubricant through #60 mesh, adding to obtained blend of step (e) and mixing for 5 minutes, and
  • the present invention provides process for preparing ferrous sulphate granules and buccal tablets, wherein the process comprising steps of:
  • step (d) adding above sifting ingredients to obtained dried granules of step (b),
  • step (e) sifting lemon flavour through #100 mesh, aerosil through #60 mesh and adding to obtained blend of step (d) followed by mixing for 10 minutes,
  • step (f) sifting purified talc through #60 mesh, adding to obtained blend of step (e) and mixing for 5 minutes, and
  • Anaemia is a condition in which the number of red blood cells or their oxygen carrying capacity is insufficient to meet physiologic needs, which vary by age, sex, altitude, smoking, and pregnancy status. Iron deficiency is thought to be the most common cause of anaemia globally, although other conditions, such as folate, vitamin B12 and vitamin A deficiencies, chronic inflammation, parasitic infections, and inherited disorders can all cause anaemia. In its severe form, it is associated with fatigue, weakness, dizziness and drowsiness. Pregnant women and children are particularly vulnerable.
  • the present invention is to provide granules and buccal tablets compositions comprising ferrous sulphate hydrate as active ingredient, penetration/absorption enhancers and pharmaceutically acceptable excipients and its process of preparation.
  • the present invention is to provide granules and buccal tablets compositions comprising ferrous sulphate hydrate as active ingredient, anti-oxidant, mouth melting agent, taste masking agents as penetration/absorption enhancers, reducing agent, binding agent, sweetening agent, disintegrant, flavouring agent and lubricants as pharmaceutically acceptable excipients.
  • the term“active ingredient” of the present invention is used to prevent anemia.
  • the active ingredient is Iron compound or pharmaceutically acceptable salts, esters, solvates, derivatives, polymorphs or hydrates thereof.
  • iron salts include, but are not limited to ferrous sulfate, ferrous citrate, ferrous ascorbate, ferrous fumarate, ferrous glycinate, ferrous gluconate.
  • Preferably used active ingredient is ferrous sulphate hydrate. Most preferably used active ingredient is ferrous sulphate heptahydrate.
  • prevent refers to avoidance, prevention and/or delay of the onset of a disease, disorder and/or a clinical symptom(s) in a subject and/or a reduction in the severity of the onset of the disease, disorder and/or clinical symptom(s) relative to what would occur in the absence of the methods of the invention.
  • the prevention can be complete, e.g., the total absence of the disease, disorder and/or clinical symptom(s).
  • the prevention can also be partial, such that the occurrence of the disease, disorder and/or clinical symptom(s) in the subject and/or the severity of onset is less than what would occur in the absence of the present invention.
  • iron deficiency refers to any disease or disorder in which whole body stores of iron are less than desired.
  • Low body stores may be indicated by various symptoms including a blood level of iron that is below normal, low ferritin levels, and/or low haemoglobin levels.
  • Exemplary low levels may be a cause and/or symptom of the disease or disorder and includes any disease or disorder in which elevating iron levels in the subject, e.g., in the blood, treats and/or prevents one or more symptoms of the disease or disorder, or where maintenance of iron indices is required for effectiveness of another agent, e.g., erythropoiesis- stimulating agents.
  • the normal serum iron level for human adults is considered to be about 50 to about 170 pg/dL.
  • Ferrous sulphate occurs in different forms such as anhydrous, monohydrate, tetrahydrate and heptahydrate.
  • the most common naturally occurring form is heptahydrate with a chemical formula of FeS0 4 .7H 2 0. It is pale, bluish or whitish green, odourless crystals, crystalline powder or granules. Effloresces in dry air. In moist air it oxidizes readily to form brownish yellow basic ferric sulphate. It is functionally used as nutrient supplement.
  • the concentration of Ferrous sulphate hydrate used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 5% to 25% (w/w), preferably 5% to 15% (w/w) of the total weight of the composition.
  • Anti-oxidant used alone or in combination in the compositions of the present invention include, but are not limited to vitamin C, vitamin E, vitamin A, flavonoids, polyphenols, tocopherol, deteroxime mesylate, methyl paraben, ethyl paraben, ascorbic acid.
  • Preferably used anti-oxidant is ascorbic acid.
  • the concentration of anti-oxidant used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 5% to 25% (w/w), preferably 5% to 15% (w/w) of the total weight of the composition.
  • Reducing agents used alone or in combination in the compositions of the present invention include, but are not limited saccharides, sugar or sugar alcohol.
  • Saccharides include monosaccharides, disaccharides, trisaccharides, tetrasaccharides, or other higher polysaccharides, such as cellulose and starch.
  • Suitable monosaccharides include glucose, galactose, fructose, mannose, mannitol and sorbitol.
  • the disaccharides include maltose, lactose and sucrose.
  • Preferably used reducing agent is fructose.
  • the concentration of reducing agent used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 20% (w/w), preferably 1% to 10% (w/w) of the total weight of the composition.
  • Binding agents used alone or in combination in the compositions of the present invention include, but are not limited to carboxy vinyl polymer, methylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, gum arabic, starch, hydroxypropylmethylcellulose, polyvinylpyrrolidone, polyethylene glycol.
  • Preferably used binder is polyvinylpyrrolidone K 30.
  • the concentration of binding agent used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 10% (w/w), preferably 1% to 5% (w/w) of the total weight of the composition.
  • Lubricants used alone or in combination in the compositions of the present invention include, but are not limited to magnesium stearate, stearic acid, sodium stearyl fumarate, microcrystalline cellulose, crosslinked sodium carboxymethylcellulose, silica, aerosil, corn starch, sucrose fatty acid esters, polyethylene glycol, talc, stearic acid, calcium stearate.
  • Preferably used lubricants are aerosil and purified talc.
  • concentration of lubricants used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 5%.
  • concentration of lubricant individually is from 1% to 3% (w/w).
  • concentration of lubricant used in combination in the iron salt compositions for buccal administration of the present invention is from 1% to 10%.
  • Mouth melting agent used alone or in combination in the compositions of the present invention include, but are not limited to sugar alcohols such as sorbitol, sorbitol syrup, mannitol, xylitol, hexa-resorcinol.
  • sugar alcohols such as sorbitol, sorbitol syrup, mannitol, xylitol, hexa-resorcinol.
  • mannitol mannitol.
  • the concentration of mouth melting agent used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 10% to 90% (w/w), preferably 20% to 30% (w/w) of the total weight of the composition.
  • Disintegrants used alone or in combination in the compositions of the present invention include, but are not limited to starches such as corn starch, etc., carmellose calcium, crospovidone, lower substituted hydroxypropyl cellulose, alginic acid, sodium carboxymethyl starches, methylcellulose, agar bentonite, sodium starch glycolate, microcrystalline cellulose, colloidal silicon dioxide, guar gum, magnesium aluminum silicate, polacrilin potassium, powdered cellulose, pregelatinized starch, sodium alginate.
  • Preferably used disintegrant is crospovidone.
  • the concentration of disintegrant used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 15% (w/w), preferably 5% to 15% (w/w) of the total weight of the composition.
  • Taste masking agents used alone or in combination in the compositions of the present invention include, but are not limited to osmolality adjusting ingredient, flavouring agent and film-forming agents.
  • Osmolality adjusting ingredient is selected from potassium chloride, calcium chloride, sodium lactate, sodium chloride, dextrose, mannitol, sucrose, trehalose, and phosphate buffered saline, or mixtures thereof.
  • Flavouring agent is selected from vanillin, ethyl vanillin, menthol, citric acid, fumaric acid ethyl maltitol, and tartaric acid.
  • Film-forming agent is selected from pullulan, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, polyvinyl pyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodium alginate, polyethylene glycol, xanthan gum, tragacanth gum, guar gum, acacia gum, arabic gum, polyacrylic acid, methylmethacrylate copolymer, carboxyvinyl polymer, amylose, high amylose starch, hydroxypropylated high amylose starch, dextrin, pectin, chitin, chitosan, levan, elsinan, collagen, gelatin, zein, gluten, soy protein isolate, whey protein isolate, casein and mixtures thereof.
  • taste masking agents are sodium chloride, citric acid and whey protein.
  • the concentration of taste masking agents used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 0.5% to 20% (w/w).
  • concentration of taste masking agent individually is from 2% to 20% (w/w).
  • concentration of taste masking agent used in combination in the iron salt compositions for buccal administration of the present invention is from 20% to 35% (w/w).
  • Sweetening agents used alone or in combination in the compositions of the present invention include, but are not limited to saccharin, saccharin sodium, aspartame, maltitol, zinc gluconate, ethyl maltitol, glycine, acesulfame-K, honey, golden syrup, misri, spray dried licorice root, glycerrhizin, dextrose, sodium gluconate, stevia powder; glucono delta-lactone, ethyl vanillin, vanillin, sucrose, glucose (corn syrup), dextrose, invert sugar, fructose, sucralose, stevia, dihydrochalcone, maltodextrin, polydextrose, sugar alcohols such as sorbitol, sorbitol syrup, mannitol, xylitol, hexa-resorcinol.
  • Preferably used sweetening agent is sucralose or stevia.
  • the concentration of sweetening agent used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 5% (w/w), preferably 1% to 3% (w/w) of the total weight of the composition.
  • Flavouring agents used alone or in combination in the compositions of the present invention include, but are not limited to coffee extract, mint, lamiacea extracts, lemon flavour, almond oil, babassu oil, borage oil, blackcurrant seed oil, canola oil, castor oil, coconut oil, corn oil, cottonseed oil, evening primrose oil, grape seed oil, groundnut oil, mustard seed oil, olive oil, palm oil, palm kernel oil, peanut oil, grape seed oil, safflower oil, sesame oil, shark liver oil, soybean oil, sunflower oil; hydrogenated castor oil, hydrogenated coconut oil, hydrogenated palm oil, hydrogenated soybean oil, hydrogenated vegetable oil, hydrogenated cottonseed and castor oil, partially hydrogenated soybean oil, soy oil, glyceryl tricaproate, glyceryl tricaprylate, glyceryl tricaprate, glyceryl triundecanoate, glyceryl trilaurate, glyceryl trioleate, glyceryl trilinoleate,
  • Preferably used flavouring agent is lemon flavour.
  • concentration of falvouring agent used in the iron salt compositions for buccal administration with increased bio absorption is in the range of 1% to 10% (w/w), preferably 3% to 8% (w/w) of the total weight of the composition.
  • the ferrous sulphate granules preparation of present invention has been prepared by using wet granulation technique comprising the steps of sifting, granulating, drying and filling into sachets.
  • the ferrous sulphate hydrate buccal tablet of present invention is orally soluble with increased bioavailability. It is devoid of metallic/iron taste and easy patient compliance.
  • the ferrous sulphate hydrate buccal tablets preparation of present invention has been prepared by using wet granulation technique comprising the steps of sifting, granulating, drying and compressing.
  • the invention disclosed herein is process for the preparation of ferrous sulphate granules and buccal tablets useful in preventing anemia.
  • Ferrous sulphate and ascorbic acid were co-sifted through #80 mesh.
  • Fructose, mannitol and PVP K30 were co-sifted through #40 mesh. All these materials were blended for 5 minutes.
  • Mixed materials were wet granulated with water and dried at 45°C for 10 minutes. Dried granules were passed through #40 mesh.
  • Whey protein, sucralose, crospovidone and citric acid were co-sifted through #40 mesh and sodium chloride is sifted through #80 mesh. All these materials were added to dried granules.
  • Lemon flavour sifted through #100 mesh and aerosil is sifted through #60 mesh, added and mixed with obtained granules for 10 minutes.
  • Purified talc is sifted through #60 mesh, added and mixed with obtained granules for 5 minutes.
  • the resulting blend of granules were filled into sachets or compressed into buccal tablets using compression machine with appropriate tooling.
  • Ferrous sulphate and ascorbic acid were co-sifted through #80 mesh.
  • Fructose, mannitol and PVP K30 were co-sifted through #40 mesh. All these materials were blended for 5 minutes.
  • Mixed materials were wet granulated with water and dried at 45°C for 10 minutes. Dried granules were passed through #40 mesh.
  • Whey protein, stevia, crospovidone and citric acid were co-sifted through #40 mesh and sodium chloride is sifted through #80 mesh. All these materials were added to dried granules.
  • Lemon flavour sifted through #100 mesh and aerosil is sifted through #60 mesh, added and mixed with obtained granules for 10 minutes.
  • Purified talc is sifted through #60 mesh, added and mixed with obtained granules for 5 minutes. The resulting blend of granules were filled into sachets or compressed into buccal tablets using compression machine with appropriate tooling. Post-compression evaluation parameters of ferrous sulphate buccal tablets
  • Friability 0.61% w/w.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des granules de sel de fer et des comprimés oraux comprenant du sulfate ferreux en tant que principe actif et des excipients pharmaceutiquement acceptables de prévention contre une anémie. La présente invention concerne en outre des granules et des comprimés oraux comprenant un hydrate de sulfate ferreux en tant que principe actif, un antioxydant, un agent de fusion en bouche, des agents de masquage de goût en tant qu'activateurs de pénétration/absorption, un agent réducteur, un agent de liaison, un agent édulcorant, un délitant, un agent aromatisant et des lubrifiants en tant qu'excipients pharmaceutiquement acceptables. La présente invention concerne également un procédé pour la préparation de granules de sulfate ferreux et de comprimés oraux à l'aide d'une technique de granulation par voie humide comprenant les étapes consistant à tamiser, à granuler, à sécher et à remplir en sachets ou à compresser en comprimés oraux.
PCT/IB2020/054592 2019-05-14 2020-05-14 Compositions orales de sulfate ferreux Ceased WO2020230090A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020275505A AU2020275505A1 (en) 2019-05-14 2020-05-14 Ferrous sulphate oral compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201941019109 2019-05-14
IN201941019109 2019-05-14

Publications (1)

Publication Number Publication Date
WO2020230090A1 true WO2020230090A1 (fr) 2020-11-19

Family

ID=73288738

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/054592 Ceased WO2020230090A1 (fr) 2019-05-14 2020-05-14 Compositions orales de sulfate ferreux

Country Status (2)

Country Link
AU (1) AU2020275505A1 (fr)
WO (1) WO2020230090A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112471512A (zh) * 2020-12-13 2021-03-12 江西师范大学 一种高稳定性β-胡萝卜素微胶囊及其制备方法
CN115364064A (zh) * 2022-10-08 2022-11-22 南京比逊医药科技有限公司 一种稳定的硫酸亚铁片的制备方法
CN116530687A (zh) * 2023-06-03 2023-08-04 重庆医科大学 一种含乳酸亚铁口服溶液及其用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
CN1408352A (zh) * 2002-09-20 2003-04-09 单玉华 一类补铁剂咀嚼片的处方组成
US6610325B1 (en) * 1998-02-03 2003-08-26 Laboratoire Innothera Tablets to be crunched or sucked, comprising iron as active principle
US20120189692A1 (en) * 2011-01-07 2012-07-26 Alan Cullen Pharmaceutical Compositions of Iron for Oral Administration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US6610325B1 (en) * 1998-02-03 2003-08-26 Laboratoire Innothera Tablets to be crunched or sucked, comprising iron as active principle
CN1408352A (zh) * 2002-09-20 2003-04-09 单玉华 一类补铁剂咀嚼片的处方组成
US20120189692A1 (en) * 2011-01-07 2012-07-26 Alan Cullen Pharmaceutical Compositions of Iron for Oral Administration

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112471512A (zh) * 2020-12-13 2021-03-12 江西师范大学 一种高稳定性β-胡萝卜素微胶囊及其制备方法
CN115364064A (zh) * 2022-10-08 2022-11-22 南京比逊医药科技有限公司 一种稳定的硫酸亚铁片的制备方法
CN116530687A (zh) * 2023-06-03 2023-08-04 重庆医科大学 一种含乳酸亚铁口服溶液及其用途

Also Published As

Publication number Publication date
AU2020275505A1 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
TWI468167B (zh) 藥學組成物
AU2009243065B2 (en) Nicotine lozenge compositions
ES2380952T3 (es) Mezcla de sales de hierro y cobre que enmascaran el sabor metálico.
US20030190355A1 (en) Modified release minerals
US20080193531A1 (en) Compositions for improving gastrointestinal nutrient and drug absorption
US9011822B2 (en) Mixture of iron and copper salts masking metallic taste
CN1131538A (zh) 口服黄酮类药物组合物
WO2009067067A1 (fr) Procédé et moyens pour obtenir une bronchorelaxation
WO2020230090A1 (fr) Compositions orales de sulfate ferreux
ITMI20092198A1 (it) Ferro bisglicinato chelato per uso nel trattamento per via orale dell'anemia in pazienti celiaci.
JP2011513194A (ja) 口腔内崩壊錠
WO2014010656A1 (fr) Agent d'accélération de la baisse de concentration d'alcool supérieur dans le sang
JPWO2012001977A1 (ja) 崩壊性組成物及び易崩壊性圧縮成型物
WO2005123040A1 (fr) Pastille se désintégrant rapidement dans la bouche
WO2015020191A1 (fr) Agent calcique
JPWO2014010658A1 (ja) ヒハツ配合製剤
AU2013219211B2 (en) Nicotine lozenge compositions
EP3709994B1 (fr) Forme à administrer par voie orale comprenant un mélange de fer-cuivre et son utilisation en tant que complément alimentaire
JP2006076956A (ja) 胃炎の治療・予防用配合剤
JP7720770B2 (ja) ロキソプロフェンとグリシンを含有する固形製剤及びその製造方法
WO2010067151A1 (fr) Composition à délitement rapide et goût masqué
KR20110008773A (ko) 독소필린 함유 서방출형 미세정제 및 이의 제조방법
JP2011068614A (ja) ビタミン製剤
JP2007145731A (ja) 止瀉効果を有する内服用製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20805589

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020275505

Country of ref document: AU

Date of ref document: 20200514

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 20805589

Country of ref document: EP

Kind code of ref document: A1